World's Best Scientists 2026 revealed!
Peter F.A. Mulders

Peter F.A. Mulders

D-Index & Metrics

Medicine

D-Index
87
Citations
42382
World Ranking
13412
National Ranking
511

Peter F.A. Mulders publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter F.A. Mulders sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 470 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter F.A. Mulders D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter F.A. Mulders sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter F.A. Mulders is affiliated with Radboud University in the Netherlands and has a research focus primarily in the medical and biochemical sciences. Their scholarly output covers a range of topics including renal cell carcinoma treatment, prostate cancer treatment and research, and molecular biology techniques and applications. The scientific work also delves into radiomics and machine learning in medical imaging, as well as radiopharmaceutical chemistry and applications.

Their research is frequently published in venues such as European Urology Open Science, Tijdschrift voor Urologie, Prostate Cancer and Prostatic Diseases, Journal of Clinical Oncology, and World Journal of Urology. These journals reflect their engagement with urology, oncology, and clinical cancer research.

Recent papers by Peter F.A. Mulders include:

  • Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men (2021, Prostate Cancer and Prostatic Diseases)
  • Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology (2020, Prostate Cancer and Prostatic Diseases)
  • [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma (2022, Clinical Cancer Research)
  • Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model (2022, Pharmaceuticals)
  • Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial (2021, British Journal of Urology)

They regularly collaborate with several co-authors, including Inge M. van Oort, Egbert Oosterwijk, Stijn Muselaers, Bas Israël, and Hans de Jong. The frequency of collaboration with these researchers indicates a network within oncology and urology research fields.

Peter F.A. Mulders' research covers important subfields such as pulmonary and respiratory medicine, molecular biology, radiology, nuclear medicine and imaging, cancer research, and oncology. Main fields of study include medicine as well as biochemistry, genetics, and molecular biology.

Key research topics encompass:

  • Renal cell carcinoma treatment
  • Prostate cancer treatment and research
  • Renal and related cancers
  • Prostate cancer diagnosis and treatment
  • Radiomics and machine learning in medical imaging
  • Radiopharmaceutical chemistry and applications
  • Molecular biology techniques and applications

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • EAU Guidelines on Renal Cell Carcinoma: 2014 Update

    Borje Ljungberg;Karim Bensalah;Steven Canfield;Saeed Dabestani

  • A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.

    Thorgeir E Thorgeirsson;Frank Geller;Patrick Sulem;Thorunn Rafnar

  • GuidelinesEAU Guidelines on Renal Cell Carcinoma: The 2010 Update

    Börje Ljungberg;Nigel C. Cowan;Damian C. Hanbury;Milan Hora

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo

  • Resting-state functional connectivity in major depressive disorder: A review

    Peter C. Mulders;Philip F. van Eijndhoven;Aart H. Schene;Christian F. Beckmann

  • SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE

    Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck

  • Renal cell carcinoma guideline.

    Börje Ljungberg;Damian C. Hanbury;Marcus A. Kuczyk;Axel S. Merseburger

  • Multi-institutional validation of a new renal cancer-specific survival nomogram.

    Pierre I. Karakiewicz;Alberto Briganti;Felix K H Chun;Quoc Dien Trinh

  • Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

    Alexander Haese;Alexandre de la Taille;Hendrik van Poppel;Michael Marberger

  • Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy

    Lorenzo Marconi;Saeed Dabestani;Thomas B. Lam;Fabian Hofmann

  • Guidelines on Renal Cell Carcinoma

    Börje Ljungberg;D C Hanbury;M A Kuczyk;A S Merseburger

  • Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

    Jean Jacques Patard;Hyung L. Kim;John S. Lam;Frederick J. Dorey

  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    Christopher Wood;Pramod Srivastava;Ronald Bukowski;Louis Lacombe

  • Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer ☆

    Gisele H.J.M. Leyten;Daphne Hessels;Sander A. Jannink;Frank P. Smit

  • Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The surtime randomized clinical trial

    Axel Bex;Peter Mulders;Michael A.S. Jewett;John Wagstaff

  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

    Tomasz M. Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    J.-J. Patard;E. Leray;N. Rioux-Leclercq;L. Cindolo

Frequent Co-Authors

Jack A. Schalken
Jack A. Schalken Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Otto C. Boerman
Otto C. Boerman Radboud University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Alexandre de la Taille
Alexandre de la Taille Université Paris Cité
Fred Saad
Fred Saad University of Montreal
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Arturo Molina
Arturo Molina Sutro Biopharma
Matthew R. Smith
Matthew R. Smith Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical education, online degrees offer a flexible way to start or advance your healthcare career. From entry-level to advanced programs, many students are choosing online pathways for their affordability and convenience.

For those interested in healthcare administration, consider the cheapest medical billing and coding online courses. These programs provide quick entry into the medical field without years of schooling.

Nursing continues to be an in-demand profession. If you’re looking for accessible RN or BSN programs, look into affordable nursing programs online. These allow you to balance life and study while working toward licensure.

Ambitious nurses looking to specialize may pursue the cheapest online fnp programs. Family Nurse Practitioner (FNP) training leads to higher salaries and more independent roles.

For those pursuing leadership or academic careers, an online phd nursing can open doors to research, teaching, and executive opportunities within healthcare.

Best Scientists Citing Peter F.A. Mulders

Trending Scientists

Recently Published Articles